Acalabrutinib (ACP-196) in Combination with ACP-319, for Treatment of B-Cell Malignancies

Trial Identifier: ACE-LY-001
Sponsor: AcertaPharma
Collaborator:
AstraZeneca
Start Date: December 2014
Primary Completion Date: June 2020
Study Completion Date: April 2026
Condition: Myeloma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version

Trial Locations

Country Location
US, CA Orange, CA, US, 92868
US, MD Bethesda, MD, US, 20892
US, NY Rochester, NY, US, 14642
US, Oregon Portland, Oregon, US, 97239
US, TN Nashville, TN, US, 37203
US, TX Austin, TX, US, 78705
US, WA Seattle, WA, US, 98109